EA201491823A1 - Гетероциклические соединения и их использование - Google Patents

Гетероциклические соединения и их использование

Info

Publication number
EA201491823A1
EA201491823A1 EA201491823A EA201491823A EA201491823A1 EA 201491823 A1 EA201491823 A1 EA 201491823A1 EA 201491823 A EA201491823 A EA 201491823A EA 201491823 A EA201491823 A EA 201491823A EA 201491823 A1 EA201491823 A1 EA 201491823A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
inflammatory
leukemia
cell
acute lymphoblastic
Prior art date
Application number
EA201491823A
Other languages
English (en)
Inventor
Минна Хью Тханх Буи
Тимоти Д. Кашин
Феликс Гонсалес Лопес де Турисо
Сяолинь Хао
Брайан Лукас
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201491823A1 publication Critical patent/EA201491823A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Замещенные бициклические гетероарилы и композиции, содержащие их, для лечения общего воспаления, артрита, ревматических заболеваний, остеоартрита, воспалительных заболеваний кишечника, воспалительных заболеваний глаз, воспалительных заболеваний или нестабильности мочевого пузыря, псориаза, кожных заболеваний с воспалительными компонентами, хронических воспалительных состояний, включая аутоиммунные заболевания, такие как системная красная волчанка (SLE), тяжелая псевдопаралитическая миастения, ревматоидный артрит, острый рассеянный энцефаломиелит, идиопатический тромбоцитопенический пурпур, болезнь Шарко-Вюльпиана, синдром Шегрена и аутоиммунная гемолитическая анемия, аллергические состояния, включая все формы гиперчувствительности, но не ограничиваясь ими. Настоящее изобретение также обеспечивает способы лечения рака, которые опосредуются, зависят или связанны с р110δ активностью, в том числе лейкозов, таких как, без ограничения, острый миелоидный лейкоз (AML), миелодиспластический синдром (MDS), миелопролиферативные заболевания (MPD), хронический миелолейкоз (CML), Т-клеточный острый лимфобластный лейкоз (T-ALL), В-клеточный острый лимфобластный лейкоз (B-ALL), Неходжкинские лимфомы (NHL), В-клеточная лимфома и твердые опухоли, такие как рак молочной железы.
EA201491823A 2012-04-04 2013-04-04 Гетероциклические соединения и их использование EA201491823A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620270P 2012-04-04 2012-04-04
PCT/US2013/035203 WO2013152150A1 (en) 2012-04-04 2013-04-04 Heterocyclic compounds and their uses

Publications (1)

Publication Number Publication Date
EA201491823A1 true EA201491823A1 (ru) 2015-01-30

Family

ID=48142975

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491823A EA201491823A1 (ru) 2012-04-04 2013-04-04 Гетероциклические соединения и их использование

Country Status (31)

Country Link
US (2) US8716290B2 (ru)
EP (1) EP2834231B1 (ru)
JP (1) JP2015512451A (ru)
KR (1) KR20140139547A (ru)
CN (1) CN104395305A (ru)
AP (1) AP3611A (ru)
AU (1) AU2013243506A1 (ru)
CA (1) CA2869413A1 (ru)
CL (1) CL2014002686A1 (ru)
CO (1) CO7091181A2 (ru)
CR (1) CR20140503A (ru)
CY (1) CY1117487T1 (ru)
DK (1) DK2834231T3 (ru)
EA (1) EA201491823A1 (ru)
ES (1) ES2577109T3 (ru)
HR (1) HRP20160352T1 (ru)
HU (1) HUE028762T2 (ru)
IL (1) IL234822A0 (ru)
MA (1) MA37472A1 (ru)
ME (1) ME02473B (ru)
MX (1) MX2014011970A (ru)
PE (1) PE20142457A1 (ru)
PH (1) PH12014502246A1 (ru)
PL (1) PL2834231T3 (ru)
RS (1) RS54716B1 (ru)
SG (1) SG11201406316VA (ru)
SI (1) SI2834231T1 (ru)
SM (1) SMT201600211B (ru)
TN (1) TN2014000412A1 (ru)
WO (1) WO2013152150A1 (ru)
ZA (1) ZA201407037B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013005567A (es) * 2010-11-17 2013-10-30 Amgen Inc Derivados de quinolina como inhibidores de pik3.
EA201491823A1 (ru) * 2012-04-04 2015-01-30 Эмджен Инк. Гетероциклические соединения и их использование
AR100289A1 (es) 2014-05-06 2016-09-21 Amgen Inc Formas de un inhibidor de pi3k
CU24428B1 (es) 2014-07-04 2019-06-04 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
WO2017155741A1 (en) 2016-03-05 2017-09-14 Zhejiang Vimgreen Pharma Ltd. Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
US7879853B2 (en) * 2004-06-28 2011-02-01 Bayer Schering Pharma Ag 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
PT2139882E (pt) * 2007-03-23 2014-01-30 Amgen Inc Derivados de quinolina ou quinoxalina 3-substituídos e sua utilização como inibidores de fosfatidilinositol 3-cinase (pi3k)
US8399483B2 (en) * 2007-12-21 2013-03-19 Ucb Pharma S.A. Quinoxaline and quinoline derivatives as kinase inhibitors
CA2745280A1 (en) * 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
US20100331306A1 (en) * 2009-06-25 2010-12-30 Amgen Inc. Heterocyclic compounds and their uses
WO2011075628A1 (en) * 2009-12-18 2011-06-23 Amgen Inc. Heterocyclic compounds and their uses
MX2012015134A (es) * 2010-07-02 2013-05-06 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
EA201491823A1 (ru) * 2012-04-04 2015-01-30 Эмджен Инк. Гетероциклические соединения и их использование

Also Published As

Publication number Publication date
US20130267524A1 (en) 2013-10-10
AU2013243506A1 (en) 2014-10-09
AP2014007979A0 (en) 2014-09-30
CY1117487T1 (el) 2017-04-26
JP2015512451A (ja) 2015-04-27
MX2014011970A (es) 2015-05-12
MA37472A1 (fr) 2016-09-30
SMT201600211B (it) 2016-08-31
RS54716B1 (en) 2016-08-31
US20140206694A1 (en) 2014-07-24
ME02473B (me) 2017-02-20
SG11201406316VA (en) 2014-11-27
EP2834231B1 (en) 2016-03-30
CL2014002686A1 (es) 2015-05-08
CA2869413A1 (en) 2013-10-10
HUE028762T2 (en) 2016-12-28
PL2834231T3 (pl) 2016-07-29
KR20140139547A (ko) 2014-12-05
ES2577109T3 (es) 2016-07-13
US8835432B2 (en) 2014-09-16
CR20140503A (es) 2015-03-06
CN104395305A (zh) 2015-03-04
ZA201407037B (en) 2015-11-25
PE20142457A1 (es) 2015-02-07
HRP20160352T1 (hr) 2016-05-06
WO2013152150A1 (en) 2013-10-10
CO7091181A2 (es) 2014-10-21
PH12014502246A1 (en) 2014-12-15
AP3611A (en) 2016-02-29
US8716290B2 (en) 2014-05-06
IL234822A0 (en) 2014-12-31
EP2834231A1 (en) 2015-02-11
TN2014000412A1 (en) 2015-12-21
SI2834231T1 (sl) 2016-09-30
DK2834231T3 (en) 2016-04-18

Similar Documents

Publication Publication Date Title
EA201291005A1 (ru) Гетероциклические соединения и их применение
EA201270013A1 (ru) Гетероциклические соединения и их применение
EA201491823A1 (ru) Гетероциклические соединения и их использование
MX2012015134A (es) Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
EA200901276A1 (ru) Гетероциклические соединения и их применение
MX2013007261A (es) Compuestos heterociclicos y sus usos.
MX2012015135A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
EA201270051A1 (ru) Гетероциклические соединения и их применения
MX2011013901A (es) Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
MX2011013667A (es) Compuestos heterociclicos y sus usos.
MX2009010050A (es) Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
MX2009009913A (es) Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres.
MX2012015143A (es) Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
MX2012015147A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
MX2020001236A (es) Compuestos aza biciclicos como agonistas del receptor muscarinico m1.
EA201592033A1 (ru) 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА
EA201500816A1 (ru) Замещенные бициклические дигидропиримидиноны и их применение в качестве ингибиторов активности нейтрофильной эластазы
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
EA201492250A1 (ru) Гетероциклическое соединение
MX2018009408A (es) Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos.
AR090705A1 (es) Compuestos de piridina y pirimidina y sus usos como inhibidores de fosfatidilinositol 3-quinasa (pi3k)
CY1117196T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1114775T1 (el) Παραγωγα 3-υποκατεστημενης κινολινης ή κινοξαλινης και η χρηση τους ως αναστολεων της 3-κινασης φωσφατιδυλινοσιτολης (ρι3κ)
UY34748A (es) Compuestos heterocíclicos y sus usos